File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Interfron therapy of chronic hepatitis B virus infection in Chinese

TitleInterfron therapy of chronic hepatitis B virus infection in Chinese
Authors
Issue Date1986
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 1986, v. 3 SUPPL. 2, p. S209-S215 How to Cite?
AbstractHepatitis B virus (HBV) infection is prevalent in Chinese populations. 40.4% of 383 Chinese HBV carriers studied were HBeAg-positive. The annual rate of spontaneous clearance of HBeAg was 11%. Twenty-six patients with HBsAg- and HBeAg-positive non-malignant chronic liver disease randomised to receive recombinant α-2 interferon or no treatment have been followed for 6 months or longer. Seven of the 20 treated patients cleared HBeAg during or shortly after treatment but this was sustained in only 1 patient. One of the 6 controls had transient loss of HBeAg. It is too early to conclude whether interferon has any long-term effect on the suppression of HBV replication in Chinese patients. Sixty-nine patients with histologically proven hepatocellular carcinoma were randomised to receive adriamycin or interferon. Although there was no significant benefit on survival, interferon therapy was associated with >25% regression in tumor size in 12.5% of patients and less toxicity.
Persistent Identifierhttp://hdl.handle.net/10722/161713
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.date.accessioned2012-09-05T05:14:16Z-
dc.date.available2012-09-05T05:14:16Z-
dc.date.issued1986en_US
dc.identifier.citationJournal Of Hepatology, 1986, v. 3 SUPPL. 2, p. S209-S215en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/161713-
dc.description.abstractHepatitis B virus (HBV) infection is prevalent in Chinese populations. 40.4% of 383 Chinese HBV carriers studied were HBeAg-positive. The annual rate of spontaneous clearance of HBeAg was 11%. Twenty-six patients with HBsAg- and HBeAg-positive non-malignant chronic liver disease randomised to receive recombinant α-2 interferon or no treatment have been followed for 6 months or longer. Seven of the 20 treated patients cleared HBeAg during or shortly after treatment but this was sustained in only 1 patient. One of the 6 controls had transient loss of HBeAg. It is too early to conclude whether interferon has any long-term effect on the suppression of HBV replication in Chinese patients. Sixty-nine patients with histologically proven hepatocellular carcinoma were randomised to receive adriamycin or interferon. Although there was no significant benefit on survival, interferon therapy was associated with >25% regression in tumor size in 12.5% of patients and less toxicity.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.subject.meshCarcinoma, Hepatocellular - Therapyen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDoxorubicin - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Ethnology - Therapyen_US
dc.subject.meshHepatitis B E Antigens - Analysisen_US
dc.subject.meshHepatitis, Chronic - Therapyen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Therapeutic Useen_US
dc.subject.meshLiver Neoplasms - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshRecombinant Proteins - Therapeutic Useen_US
dc.titleInterfron therapy of chronic hepatitis B virus infection in Chineseen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0168-8278(86)80122-2-
dc.identifier.pmid3036936-
dc.identifier.scopuseid_2-s2.0-0022965251en_US
dc.identifier.volume3en_US
dc.identifier.issueSUPPL. 2en_US
dc.identifier.spageS209en_US
dc.identifier.epageS215en_US
dc.identifier.isiWOS:A1986H386800030-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats